Elsevier MDL introduces MDL® Notebook

Major ongoing initiative delivers electronic lab notebook for simplifying R&D tasks, integrating workflow and translating scientists’ data into corporate-wide asset

San Leandro, CA - December 13, 2005 - Elsevier MDL has delivered ahead of schedule the initial release of a major electronic lab notebook (ELN) initiative announced in March 2005. MDL® Notebook gives scientists a central hub to simplify their work, capture data, document processes and make essential information available throughout a research organization. Additional releases planned for 2006 and beyond will expand capabilities for scientific disciplines, building on MDL informatics and integration strengths to deliver comprehensive workflow solutions for researchers.

Elsevier MDL, the leading informatics, database and workflow solution provider for life sciences R&D, has ten years of experience building custom ELNs for global pharmaceutical companies. MDL Notebook and the ELN initiative draw from the company’s unequaled experience in integrating workflows and providing access to contextually relevant information, backed by state-of-the-art cheminformatics technology and globally scalable solutions.

“Scientists – particularly chemists – traditionally fill paper notebooks with vital information that is very difficult to effectively capture and disseminate,” said Trevor Heritage, Senior Vice President, Workflow Business Group, Elsevier MDL. “MDL Notebook brings systematic efficiency to fundamental research activity by streamlining workflows, improving productivity and integrating information throughout R&D organizations. Elsevier MDL’s expertise in reaction databases and experience with custom electronic notebooks contribute to a comprehensive system that is unrivaled in integration capabilities, chemistry know-how and IT performance.”

MDL Notebook provides scientists with a hub for total workflow integration. From the MDL Notebook, scientists can store experiment protocols, share hypotheses with colleagues and legally document discoveries. The system streamlines workflows, automates repetitive tasks and allows scientists to easily create reports and collaborate. They can search corporate, third-party and in-house databases and perform reaction transformation searches, to immediately access relevant information in useful context.

Elsevier MDL market leadership in chemistry representation and reaction databases powers unique benefits in MDL Notebook. Synthetic chemists can utilize tools for single and multi-step reactions and discrete and parallel synthesis and reaction information is captured in a true reaction database that supports reaction substructure searches.

The convenience that MDL Notebook provides scientists translates into significant organizational benefits. By saving time, reducing costs, enhancing collaboration and helping researchers focus on science, MDL Notebook offers systematic efficiency to fundamental R&D activities. MDL Notebook brings scalable, enterprise-strength power to the user-authentication and audit functions required for due diligence and patent applications. It supports multi-site, multi-national operations, can be interfaced to corporate LIMS and is backed by a worldwide customer care organization.

MDL Notebook is part of a growing, new generation of MDL workflow tools available to researchers today. For more information about MDL workflow applications visit www.mdl.com.


About Elsevier MDL
Elsevier MDL provides informatics, database and workflow solutions that accelerate successful life sciences R&D by improving the speed and quality of scientists’ decision making. Researchers around the world depend on Elsevier MDL for innovative and reliable discovery informatics software solutions and services augmented by 400 Elsevier chemistry and life sciences journals and related products. For more information, visit www.mdl.com. Elsevier is a world-leading publisher of scientific, technical and medical information products and services.

Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), EL (London Stock Exchange), RUK and ENL (New York Stock Exchange). For more information, visit www.reedelsevier.com.

About Elsevier
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com

For more information please contact:
Dr. Phil McHale
Elsevier MDL
VP, Market and Corporate Communications
(510) 357-2222 ext. 3541

MDL and Isentris are registered trademarks of MDL Information Systems, Inc. (‘Elsevier MDL’) in the United States. All rights reserved. All other trademarks mentioned in this document are the property of their respective owners.